Broken String Biosciences has launched BaseMap ABE, a new platform designed to identify unintended off-target editing events in adenine base editing (ABE) applications. According to the company and reporting from OneNucleus, the tool uses INDUCE-seq technology to generate genome-wide data directly from biologically relevant cells rather than relying on prediction-based models.
How BaseMap ABE Tracks Off-Target Genomic Changes
Base editing allows for precise single-base genomic changes, but the risk of unintended edits remains a primary concern for therapeutic development. Broken String Biosciences states that BaseMap ABE provides a standardized method to characterize these off-target events under physiologically relevant conditions.
Unlike predictive software, this platform generates empirical data from actual cells. This approach helps researchers with editor selection, guide optimization, and preclinical decision-making by providing a clear view of editor specificity. According to Broken String Biosciences, the launch marks the first phase of the company’s expansion into base editing applications.
Did you know? Adenine base editing (ABE) is a next-generation editing modality.
Early Access Program for Therapeutic Researchers
The company is currently offering an Early Access Program to collaborate with researchers developing genome editing therapies. This program is designed to provide early adopters with first-hand experience while allowing Broken String Biosciences to use researcher feedback to inform future product iterations.
Terry Pizzie, CEO of Broken String Biosciences, stated that as gene editing technologies evolve, it is necessary for researchers to “wholly understand where and how frequently off-target editing occurs.” Pizzie noted that extending the portfolio to support ABE enables scientists to characterize outcomes for one of the most promising next-generation editing modalities.
Comparing Empirical Data vs. Prediction-Based Approaches
The industry has traditionally relied on prediction-based tools to guess where a gene editor might miss its mark. However, Broken String Biosciences argues that BaseMap ABE’s ability to generate genome-wide data directly from cells offers a more robust and unbiased identification of off-target events.
| Approach | Methodology | Primary Benefit |
|---|---|---|
| Prediction-Based | Algorithmic forecasting | Speed and initial screening |
| BaseMap ABE | Empirical cell-based data | Physiological accuracy and unbiased detection |
The Role of INDUCE-seq Technology
BaseMap ABE is built upon the company’s established INDUCE-seq platform. By applying this technology to ABE, the company aims to accelerate the development of genetic medicines that are both safer and more effective by reducing the uncertainty surrounding genomic specificity.
Pro Tip: When selecting a base editor, prioritize platforms that provide empirical, genome-wide off-target data to support guide optimization, editor selection and preclinical decision making.
Frequently Asked Questions
What is BaseMap ABE?
It is a platform developed by Broken String Biosciences to identify and characterize unintended off-target editing events in adenine base editing (ABE) applications.
How does it differ from other methods?
According to the company, it generates genome-wide data directly from biologically relevant cells rather than relying on prediction-based software.
What technology powers BaseMap ABE?
The platform is built on Broken String Biosciences’ INDUCE-seq technology.
Want to stay updated on the latest in gene editing and biotech?
Worth a look